These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 1353658

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Desensitization to sulfasalazine.
    Hessemer CA, Schinagl EF.
    Am J Gastroenterol; 1993 Mar; 88(3):460-1, 462. PubMed ID: 8094941
    [No Abstract] [Full Text] [Related]

  • 3. Desensitization to sulfasalazine after hypersensitivity reactions in patients with inflammatory bowel disease.
    Korelitz BI, Present DH, Rubin PH, Fochios SE.
    J Clin Gastroenterol; 1984 Feb; 6(1):27-31. PubMed ID: 6142067
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Treatment of ulcerative colitis with oral 5-aminosalicylic acid including patients with adverse reactions to sulfasalazine.
    Habal FM, Greenberg GR.
    Am J Gastroenterol; 1988 Jan; 83(1):15-9. PubMed ID: 2892391
    [Abstract] [Full Text] [Related]

  • 7. Inflammatory bowel diseases, 5-aminosalicylic acid and sulfasalazine treatment and risk of acute pancreatitis: a population-based case-control study.
    Munk EM, Pedersen L, Floyd A, Nørgård B, Rasmussen HH, Sørensen HT.
    Am J Gastroenterol; 2004 May; 99(5):884-8. PubMed ID: 15128355
    [Abstract] [Full Text] [Related]

  • 8. The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis.
    Baker DE, Kane S.
    Rev Gastroenterol Disord; 2004 May; 4(2):86-91. PubMed ID: 15185719
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Inflammatory bowel disease.
    Van Rosendaal GM.
    CMAJ; 1989 Jul 15; 141(2):113-23; discussion 123-4. PubMed ID: 2568163
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Salicylic derivatives in the clinical treatment of inflammatory bowel disease: new perspectives].
    Damião AO, Sipahi AM.
    Rev Hosp Clin Fac Med Sao Paulo; 1989 Jul 15; 44(5):271-8. PubMed ID: 2576896
    [Abstract] [Full Text] [Related]

  • 13. Oral desensitization to 5-aminosalicylic acid medications.
    Stelzle RC, Squire EN.
    Ann Allergy Asthma Immunol; 1999 Jul 15; 83(1):23-4. PubMed ID: 10437811
    [Abstract] [Full Text] [Related]

  • 14. Adverse effects with oral 5-aminosalicyclic acid.
    Fardy JM, Lloyd DA, Reynolds RP.
    J Clin Gastroenterol; 1988 Dec 15; 10(6):635-7. PubMed ID: 2906645
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Chronic inflammatory intestinal disease and nephritis].
    Behrens R, Ruder H.
    Klin Padiatr; 1992 Dec 15; 204(1):61-4. PubMed ID: 1346814
    [Abstract] [Full Text] [Related]

  • 18. The state of the art in the management of inflammatory bowel disease.
    Hanauer SB, Present DH.
    Rev Gastroenterol Disord; 2003 Dec 15; 3(2):81-92. PubMed ID: 12776005
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.